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Summary We studied the growth characteristics and hypoxic fractions of DLD-2 human colon tumours
xenografted into male nude mice either in the unperturbed state or after i.p. injection (q.i.d. x 7) of basic
fibroblast growth factor (0.25 mg kg-') or suramin (50 mg kg-'). Hypoxic fractions were measured by
clonogenic excision assay 1 day after administration b FGF or suramin was stopped. As compared to controls,
the growth of tumours in b FGF treated mice was increased by a factor of 1.5 as indicated by the relative
volumes of tumours on the day of excision. Similarly, suramin decreased the growth of DLD-2 tumours by a
factor of 1.6. The percentage of hypoxic cells in control neoplasms was 42.9% (95% confidence limits
34.2-52.1%). In mice that received basic fibroblast growth factor injections, hypoxic fractions decreased to
19.1% (95% confidence limits 13.5-26.9%). In contrast, in mice treated with suramin, the percentage of
hypoxic cells increased to 74.0% (95% confidence limits 65.3-83.9%). These data indicate that the biology of
solid tumours can be significantly modified by alteration of growth factor status.
Moulder and Rockwell (1984) and Rockwell and Moulder
(1990) have summarised the extent of hypoxia in various
model tumour systems. In these reviews, the authors note
that it is important to remember that quoted 'percentages' of
hypoxia within tumours represent instantaneous steady-state
values within dynamic systems. Examples of this dynamism
are the increased hypoxic levels seen as tumour size increases
(summarised in Rockwell & Moulder, 1990), and the tran-
sients in hypoxic percentages seen during the postirradiation
process of reoxygenation (Kallman & Dorie, 1986). In addi-
tion, we have recently shown (Leith et al., 1991a) that the
steady-state levels of hypoxia (about 10.5%) existing within
unperturbed xenografted human A431 epidermoid carcinomas
could be significantly altered by modification of the host
growth factor status. Specifically, removal of the salivary
glands in mice, which significantly reduces the circulating
levels of epidermal growth factor (EGF), slowed volumetric
tumour growth and concomitantly increased hypoxic frac-
tions (to about 35%). Conversely, daily injections of EGF
(0.25 mg kg-' day-1) in nonsialoadenectomised mice in-
creased tumour growth and decreased hypoxic fractions (to
about 3.5%). Therefore, systemic levels of growth factors
that possess mitogenic and/or angiogenic properties (e.g.,
EGF) may be important in expression of intraneoplastic
hypoxia. As improving tumour response and curability with
ionising radiation is a major research focus, manipulation of
intratumour hypoxia using growth factors is worthy of fur-
ther study.
To this end, we have investigated the DLD-2 xenografted
human colon tumour system with respect to growth factor
modulation of intratumour hypoxia by two additional
treatments. First, we administered a different growth factor -
basic fibroblast growth factor (b FGF), which has been
reported to affect tumour growth (Gross et al., 1990).
Second, we administered an agent which blocks growth fac-
tor receptors, suramin, and which has been shown to inhibit
the growth of xenografted human osteosarcomas (Walz et al.,
1991). The reasons for choosing the DLD-2 tumour model
for these investigations were 2-fold. First, we have previously
studied this tumour system in vivo, in regard to unperturbed
volumetric growth and radiosensitivity (assayed by tumour
growth delay) (Dexter et al., 1984). Second, as stated, Gross
et al. (1990) have studied volumetric responses ofxenografted
DLD-2 tumours to daily injection with b FGF and found
increased tumour growth rates. Therefore, based on the re-
sponse of DLD-2 xenografted human colon tumours to
b FGF as noted by Gross et al. (1990), and on our previous
studies on the responses of A431 tumours to FGF, we
hypothesised that treatment of DLD-2 tumours with b FGF
in vivo would decrease hypoxic fractions. Similarly, based on
previous results showing decreased hypoxic fractions in A431
tumours after sialoadenectomy, we hypothesised that
suramin treatment would increase hypoxic fractions. Our
results verify these hypotheses, that is, daily injections of
b FGF decreased intratumour hypoxic fractions, and in-
creased volumetric growth rates, while daily injections of
suramin decreased growth rates and increased the extent of
intratumour hypoxia.
Materials and methods
Cell line
The DLD-2 human colon adenocarcinoma cell line was
established in 1978 at the Roger Williams Cancer Center,
Providence, RI from a patient with a well to moderately well
differentiated primary adenocarcinoma of the colon. Details
on this cell line have been previously published (Crabtree et
al., 1981; Dexter et al., 1979). For these experiments, stock
cells stored in liquid nitrogen were grown in RPMI-1640
medium containing 10% foetal bovine serum (FBS), 1%
sodium bicarbonate, 1% anti-PPLO reagent, 1% 4-(2-
hydroxyethyl)-I-piperazineethanesulfonic acid buffer, and
0.04% gentamicin (all reagents from the Grand Island
Biological Co., Grand Island, NY).
Mice andproduction ofxenografted tumours
Young adult male nude mice were obtained from the Charles
River Breeding Laboratories, North Wilmington, MA. Mice
were housed, 5-10 per large cage, with dust covers, in a
dedicated room in the Brown University Animal Care
Facilities in a laminar flow hood (Thoren Industries, King of
Prussia, PA). Mice were quarantined for 1 week, and were
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ear tagged for identification. To produce tumours (one
tumour per animal), DLD-2 cells were trypsinised (0.05%
trypsin, 0.54 mM EDTA) from exponentially growing cul-
tures, and resuspended as single cells in Hank's basic salt
solution (HBSS) at a concentration of 5 x I07cells ml-'.
0.2 ml of the cell suspension was injected into the right flank
regions of the mice.
Volumetric procedures
In this work, we followed the protocol used in our previous
study of modification of hypoxic fractions in A431 xeno-
grafted tumours by EGF (Leith et al., 1991a). Tumours were
measured in two orthogonal diameters and volumes (mm3)
were calculated using the formula for a prolate ellipsoid [V
(mm3) = (L x W2)/2] where L and W are respectively the
major and minor diameters (Leith et al., 1991a,b). All
measurements were made by a single individual. After injec-
tion, tumours were monitored until average tumour sizes
were 211 mm3, at which time animals were randomly
assigned to control, b FGF treated, or suramin treated
groups.
Treatment ofnude mice bearing DLD-2 xenografts with b FGF
or suramin
We used recombinant human basic fibroblast growth factor
(purity >98%) obtained from Bachem Bioscience, Inc.,
Philadelphia, PA. The b FGF was reconstituted from
lyophilised power in HBSS, and stored for short times at
- 20°C in HBSS at a concentration of 1 tLgpl-'. The
endotoxin level as noted by the company was less than
0.1 ng pg-' of b FGF. b FGF was administered i.p. at a dose
of 0.25 mg kg-' day-' for a period of 7 days.
Suramin, the hexasodium salt of 3,3-urenylene bis[8-(3-
benzamido-4-methylbenzamido)-1,3,5-napthalene] trisulfonic
acid, was obtained from FBA pharmaceuticals Inc., West
Haven, CT. The suramin was dissolved in HBSS and injected
i.p. within 30 min at a dose of 50 mg kg'I day-', also for a
period of 7 days. Sham injections for both b FGF and
suramin were given with HBSS.
Determination ofhypoxicfractions ofxenografted DLD-2
tumours
Tumours were irradiated in either air-breathing, unanaes-
thetised mice or mice that had been asphyxiated by a 10 min
exposure to nitrogen gas prior to irradiation, as we have
previously reported (Leith et al., 1991a,b). For irradiations,
mice were briefly anaesthetised with Metofane (methyoxy-
flurane; Pitman-Moore, Inc., Washington Crossing, NJ) and
restrained on a lucite irradiation platform. Animals were
allowed to fully recovery from the anaesthesia, and were then
irradiated at room temperature using a Philips 250 kVp
X-ray machine (Philips Ltd., Einthoven, the Netherlands),
operated at 250 kV and 15 mA. Exposure doses were measured
using a Victoreen R-meter (Victoreen Co., Cleveland, OH),
and absorbed doses were calculated using appropriate
temperature, pressure, and Roentgen to Gy conversion fac-
tors. The absorbed dose rate was about 1 Gy min-'.
For determination of clonogenic cell survival by excision
assay, we delivered graded doses of 0-25 Gy to oxic and
hypoxic tumours. In the b FGF or suramin treated mice,
doses from 5-25 Gy were given. Immediately after irradia-
tion, neoplasms were excised under sterile conditions, quart-
ered, placed into ice-cold HBSS, and weighed. Then the
pieces were minced using opposed scalpel blades into approxi-
mately 1 mm3 fragments, and placed into an enzyme cocktail
containing 0.2% RNase free DNase (Sigma Chemical Co.,
St. Louis, MO), 0.25% collagenase (Boehringer Mannheim
Biochemicals, Indianopolis, IN), and 0.25% neutral protease
(Calbiochem Corp., San Diego, CA) in RPMI-1640 medium
without FBS. Tumour fragments were digested for 40 min at
37°C in stirred 250 ml trypsinising flasks. The digestate was
filtered through an 80tM rectangular stainless steel mesh and
pelleted (after addition of an equal volume of cold RPMI-
1640 medium with FBS) at 1,000r.p.m. for 10min at 4°C.
The pellet was resuspended in RPMI-1640 medium with
FBS, tumour cells were counted using phase contrast micro-
scopy, and appropriate numbers of cells were then seeded
into 60 or 100mm diameter plastic dishes (B-D Labware,
Trenton, NJ) at several dilutions for enumeration of survival
by colony formation. Heavily irradiated (30 Gy, '37CS
gamma-rays; Model 68A irradiator, J.L. Sheperd Co., Glen-
dale, CA) DLD-2 feeder cells (FCs) were added to all dishes
to keep a minimum cell number of I05 cells/60 mm dish
because the colony forming efficiencies of DLD-2 cells is FC
dependent (J. Leith, unpublished data, 1992). Colonies were
allowed to develop at 37°C in a humidified incubator under
an atomosphere of 5% CO2 and 95% air for 10-14 days,
after which time colonies were fixed and stained with 0.5%
crystal violet in absolute methanol. Colonies were inspected
microscopically to ensure that no counting bias was incurred
by the presence of giant cells.
Results
The injections of b FGF or suramin did not result in any
alterations of animal weight over the time period tested,
indicating no systemic toxicity. Higher levels of b FGF and
suramin have been shown to induce toxicity in vivo (Gross et
al., 1990; La Rocca et al., 1990).
The normalised volumetric growth curves for the control,
b FGF or suramin treated DLD-2 xenografted tumours are
shown in Figure 1. Tumours reached average volumes of
about 100 mm3 at about 12 days after implantation. Treat-
ment (b FGF, suramin, or HBSS sham-injections) was begun
on day 15 postimplantation, when tumour size was 211 mm3
(SEM 18.8 mm3), and continued for 7 days. Tumour excisions
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Figure 1 Volumetric growth of xenografted human DLD-2
tumours in nude mice (means and SEMs). Values are normalised
to the day of beginning of treatment (day 0), average tumour
volumes at this time were 211 mm3. Data are shown for tumour
growth in animals receiving i.p. injections (q.i.d. x 7) of basic
fibroblast growth factor (0, 0.25 mgkg-' day-'), Hank's basic
salt solution (0, control mice), or suramin (A, 50 ngkg-'
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for estimation of hypoxic fractions were performed 1 day
after the end of treatment (day 8). At this time, the average
volumes of control tumours were 992 mm3, 1751 mm3 for
b FGF tumours, and 654 mm3 for suramin treated tumours.
The time needed to double in volume from the start of
treatment was 1.6 days for the b FGF treated tumours, 3.9
days for suramin treated tumours, and 2.4 days for the
control neoplasms, indicating that while b FGF increased
growth by a factor of about 1.5, suramin decreased growth
by a factor of about 1.6.
Cell yields from control or b FGF/suramin treated DLD-2
tumours were not significantly different. The mean cell yield
was 2.89 x I0 cellsmg-' (95% confidence limits 2.29-
3.49 x 104cells mg-'), a value very similar to the average
yield from dissociated xenografted human colon tumours
(Leith et al., 1991b) as a class. The colony forming
efficiencies (CFEs) of the three groups were respectively
3.95% (controls), 3.56% (b FGF treated) and 3.49%
(suramin treated). The overall CFE of 3.66% (95% confi-
dence limits 3.24-4.14%) was however in the lowest quartile
in regard to values obtained from excision assay of xeno-
grafted colon tumours as a class, where the mean CFE was
27%.
The clonogenic X-ray survival curves for cells from con-
trol, b FGF, or suramin treated tumours are shown in Figure
2. The dose-response curves for the cells from the various
conditions (i.e., hypoxic, oxic, oxic plus b FGF or suramin)
are parallel, fulfilling the necessary requirement for deter-
mination of hypoxic fractions (Moulder & Rockwell, 1984).
The b FGF and suramin administrations have clearly affected
the hypoxic fractions (HFs) in the DLD-2 tumours as noted
by the shifts in the position of the survival curves. Hypoxic
fractions were calculated using the paired survival curve
method for irradiated cells from tumours in air-breathing (SO)
or in nitrogen gas asphyxiated mice (Sh) (Moulder & Rock-
well, 1990), in which the log of the HF is given by the
vertical distance between the parallel curves at any given
dose:
log (HF) = log (S.)-log (Sh)
The geometric mean HFs and their 95% confidence limits
were determined from the four estimates of HF obtained by
comparing oxic and hypoxic survival at dose levels of 10, 15,
20 and 25 Gy. These values for the unperturbed, b FGF, and
suramin conditions were respectively 0.422 (0.342-0.521),
0.191 (0.135-0.269), and 0.740 (0.653-0.839). Therefore,
b FGF treatment produces a stastically significant decrease in
the hypoxic fractions of these DLD-2 neoplasms, while
suramin produces a statistically significant increase.
Discussion
We have previously assayed the hypoxic fractions of 11 other
xenografted human colon tumours at comparable sizes to the
work reported herein on the DLD-2 tumour model (Leith et
al., 1991b). In the previous work, the geometric mean
hypoxic percentage of the 11 tumours was 8.6% (95% confi-
dence limits 2.8-25.9%), indicating that transplanted col-
orectal tumours as a class typically exhibit low steady-state
levels of hypoxia. Only one tumour system (HCT-8) exhibited
unusually high levels of intratumour hypoxia (about 82%).
In this regard, the new data from analysis of the DLD-2
tumour system indicates a relatively high level of hypoxia in
the unperturbed state (i.e., about 42%), which would alter
the estimate of the geometric mean hypoxic percentage of
colorectal tumours as a class to 9.8% (95% confidence limits
3.5-27.8%). The DLD-2 tumour appears to be an excellent
model system. With steady-state hypoxic levels of 42%,
changes in either direction produced by various treatments
(e.g., EGF, b FGF, suramin) can be demonstrated with
efficiency. Additionally, of all the excision assay studies that
we have performed on different xenografted human colon
tumours (Leith et al., 1991b), the DLD-2 system exhibits the
least variability in colony forming efficiency from both oxic
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Figure 2 Survival of DLD-2 cells from solid tumours after
graded dose x-irradiation. Survival is shown for cells anoxic (0)
or oxic (@) tumours from control mice, and tumours given daily i.p. doses (q.i.d. x 7) of basic fibroblast growth factor (A,
0.25 mgkg-' day-'), or suramin (A, 50mgkg-' day-). Means
and standard errors for 4-6 determinations per dose point. The
dashed line represents the survival of DLD-2 cells from in vitro
exponentially growing cultures.
and hypoxic tumours, therefore yielding estimates of HFs
that have relative smaller error estimates.
The results obtained in this study with b FGF are consist-
ent with our previous work on the effects of modulation of
EGF status in the mouse on A431 tumour growth charac-
teristics and hypoxic fractions (Leith et al., 1991a). Chronic
administration of mitogenic/angiogenic polypeptides such as
EGF and b FGF increases tumour growth rates and decreases
hypoxic fractions. The increased growth of the DLD-2
tumours with b FGF administration in our study is also
consistent with changes noted in DLD-2 xenografts by Gross
et al. (1990). Relevant to our studies, and to those of Gross
et al. (1990), a recent publication by Hori et al. (1991) has
shown that administration of b FGF neutralising antibodies
to mice bearing transplanted rodent K 1,000 tumours
inhibited tumour growth. This finding is consistent with our
results in which sialoadenectomy, which removes the major
source of endogenous EGF in the mouse, also inhibited
tumour growth (Leith et al., 1991a). Therefore, our previous results on modification of EGF levels (Leith et al., 1991a), the results presented herein on b FGF or suramin effects, the
results of Gross et al. (1990) on b FGF administration, plus the results of Hori et al. (1991) on application of b FGF
neutralising antibodies, all support the hypothesis that an
increase in the supply of angiogenic polypeptides can pro- duce increased tumour growth and decreased intratumour
hypoxia, while decreased levels produce decreased tumour
growth and increased tumour hypoxia.
A potential concern in the interpretation of the changes in hypoxic fractions seen with the b FGF or suramin treatments is that the hypoxic fractions were assayed in tumours of significantly different sizes (Figure 2). Because hypoxic frac- tions typically increase with increasing size (Rockwell & Moulder, 1990), the influence of such an effect must be
assessed for the studies reported herein. In this regard, it should be noted that even though the b FGF and suramin348 J.T. LEITH et al.
treated tumours are respectively larger and smaller than con-
trol neoplasms at the time of assay, they exhibit hypoxic
fractions that are respectively smaller and larger than the
hypoxic fraction seen in control tumours. That is, the change
in intratumoural hypoxia levels are exactly opposite to what
would be predicted solely on the basis of changes in tumour
size.
Our results indicate an inverse relationship between
tumour growth rate and levels of hypoxia. This would appear
to be contrary to intuition. As stated Rockwell & Moulder
(1990), 'it might be predicted that slowly-growing tumours
would have lower hypoxic fractions, because the vasculature
would be better able to "keep up" with the growth of the
tumour'. Whether our contrary experimental results are
unique to this specific situation in which angiogenically active
agents are involved requires further study. However, in other
situations where tumours display slower growth than in the
unperturbed state, as for example when tumours are implanted
into a site that has received previous irradiation (Milas et al.,
1989; Penhaligon et al., 1987; Leith, 1990), increased hypoxic
fractions are also found, consistent with the above results.
In summary, it is clear that descriptions of tumour growth
and expression of intratumour hypoxia involve multiple
aspects related to both the tumour and to the normal tissue.
For example, with respect to considerations of parenchymal
tumour cells, there are numerous publications that illustrate
differential nature of growth factor expression or production,
even for neoplasms within the same histological class (e.g.,
Anzano et al., 1989; Stefanik et al., 1991). Host factors
include organ-specific production of angiogenic polypeptides
which would act systemically in a paracrine or endocrine
fashion either on parenchymal tumour cells or on tumour
stroma (e.g., EGF by salivary glands, various factors by
regenerating liver) (Leith et al., 1991a; Fidler, 1991). At the
level of the local micro-environment, heparan sulfate proteo-
glycan is a major component of the extracellular matrix of
some tumours, and is also a reservoir for b FGF (Folkman et
al., 1988; Vlodavsky et al., 1991). Additionally Esko et al.
(1988) have shown that the in vivo growth of mutant tumour
cells that produce relatively low levels of heparan sulfate
proteoglycan is significantly reduced as compared to wild
type tumour cells. Therefore, if the extracellular matrix varies
(e.g., in the extent of heparan sulfate proteoglycan) from
tumour to tumour, this might also be a covariate of both
tumour growth and levels of intratumoural hypoxia. Further
research into the explicit roles of tumour and host related
factors is needed.
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